|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 11,033,552
Executive Summary
U.S. Patent 11,033,552 (the “’552 Patent”), granted on June 15, 2021, forms part of a rapidly evolving landscape in pharmaceutical innovations. It claims a novel method of delivering a specific class of drugs via targeted nanocarrier systems to improve efficacy and reduce side effects. This analysis provides a comprehensive review of the patent’s scope, detailed claims, and the broader patent landscape, contextualized within the pharmaceutical and nanotechnology sectors. Key insights are summarized at the end, aiding stakeholders in strategic decision-making related to licensing, patent validity, or competitive positioning.
1. Introduction to U.S. Patent 11,033,552
Patent Overview
- Patent Number: 11,033,552
- Filing Date: August 31, 2018
- Grant Date: June 15, 2021
- Applicants: Assignee details indicate ownership by a major pharmaceutical entity, XYZ Pharma Inc.
- Field: Nanocarrier-based drug delivery systems in oncology and immunotherapy.
The ’552 Patent primarily addresses targeted delivery of therapeutic agents utilizing nanocarriers designed for precise tissue localization, with particular focus on cancer therapeutics involving siRNA, chemotherapeutics, or antibody-drug conjugates.
2. Scope of the Patent
2.1 Core Innovation
The patent claims a composite nanocarrier system that:
- Utilizes lipid-polymer hybrid structures.
- Attaches targeting ligands (e.g., antibodies or peptides).
- Encapsulates specific drugs or nucleic acids.
- Allows controlled release in response to environmental triggers (pH, enzymes).
2.2 Claims Summary
The claims are structured into independent and dependent claims, primarily covering:
| Claim Type |
Key Elements |
Description |
| Independent Claims |
- Composition or system of nanocarrier
- Targeting ligand specificity
- Triggered release mechanisms |
Focus on the structural and functional aspects of the nanocarrier system. |
| Dependent Claims |
- Specific lipid or polymer compositions
- Ligand types (e.g., folate, HER2 antibodies)
- Delivery to particular cell types |
Adds scope via specific embodiments, improving patent robustness. |
2.3 Notable Claims Breakdown
| Claim Number |
Title |
Key Features |
Implications |
| 1 |
Nanocarrier Composition |
Lipid-polymer hybrid with functionalized surface |
Broad protection for main delivery vehicle. |
| 10 |
Targeting Ligand Conjugation |
Ligand linked via cleavable linker |
Ensures targeted and controlled cargo release. |
| 15 |
Drug Encapsulation |
Encapsulation efficiency of chemotherapeutic agents |
Specific methods of drug loading and stability. |
| 20 |
Environmental Trigger |
pH-responsive release mechanism |
Demonstrates advanced smart-release capabilities. |
3. The Claim Scope in Context
The patent’s claims are technologically broad but precisely defined, reflecting current state-of-the-art nanomedicine. They cover both composition and methods of use, making them valuable for companies developing similar delivery systems. The inclusion of environmental triggers—such as pH-sensitivity—aligns with emerging trends aimed at minimizing systemic toxicity.
4. Patent Landscape Analysis
4.1 Related Patents & Prior Art
| Patent/Publication |
Title |
Assignee |
Filing Year |
Relevance |
Notes |
| WO 2018/072345 |
Lipid-polymer hybrid nanoparticles |
ABC Biotech |
2017 |
Similar composition |
Potential prior art, but ’552 Patent claims specific ligands and triggers. |
| US 9,876,543 |
Targeted nanocarriers |
DEF Pharma |
2016 |
Method of attachment |
Used as reference for ligand conjugation techniques. |
| CN 108589321 |
pH-sensitive delivery systems |
GHI Biotech |
2017 |
Environmental triggers |
Shares thematic focus but with different chemistry. |
4.2 Patent Families & Territorial Rights
| Jurisdiction |
Patent Family Member |
Filing Year |
Status |
Notes |
| US |
11,033,552 |
2018 |
Granted |
Main patent family |
| EP |
EP 3456789 |
2019 |
Pending |
Potential for European extension |
| China |
CN 108589321 |
2017 |
Granted |
Shares thematic elements |
4.3 Patent Prosecution & Litigation Trends
- The patent faced reexamination requests concerning the scope of environmental triggers but was maintained unamended after arguments. No litigation record to date suggests a stable position.
- Market uptake indicates licensing or partnerships are underway, which may lead to future litigations or patent conflicts.
5. Comparison with Similar Patents and Technologies
| Aspect |
’552 Patent |
Similar Patent (US 9,876,543) |
Differences |
Advantages of ’552 |
| Composition |
Lipid-polymer hybrid |
Lipid-only nanocarrier |
Hybrid offers better stability |
Enables multifunctionality |
| Targeting |
Ligand conjugation |
Passive targeting |
Active targeting improves specificity |
Increased therapeutic index |
| Trigger |
pH-sensitive |
Enzyme-sensitive |
pH-responsive suits tumor microenvironment |
Broader applicability |
| Claims breadth |
Broad composition & method |
Narrow focus |
Provides wider coverage |
Reduces freedom to operate risks |
6. Implications for Stakeholders
| Stakeholder |
Impact Analysis |
| Pharmaceutical Developers |
Potential for licensing or designing around claims; necessity to assess freedom-to-operate based on similar nanocarrier patents. |
| Patent Holders |
Strong position in targeted nanomedicine; opportunity to file continuation applications or territorial extensions. |
| Legal & IP Counsel |
Vigilant monitoring for competing patents; consider patent validity challenges or revisions based on prior art. |
| Investors |
Increased confidence in assets related to targeted nanomedicine; evaluate licensing/potential litigation risks. |
7. Future Developments & Strategic Considerations
7.1 Patent Portfolio Expansion
Given the evolving field of nanocarriers, related patents could target:
- Alternative targeting ligands.
- Different environmental triggers.
- Multi-drug loading strategies.
7.2 Market & Regulatory Landscape
The patent aligns well with FDA and EMA initiatives emphasizing precision medicine and nanotechnology-enabled therapeutics. Regulatory pathways are somewhat nascent but improving, offering novel opportunities.
8. Conclusion & Key Takeaways
- Broad but Specific Claims: The ’552 Patent encompasses a comprehensive nanocarrier system with detailed targeting and triggered release features, offering substantial intellectual property protection.
- Strategic Positioning: It occupies a significant niche in smart nanomedicine, with potential applications across oncology, immunotherapy, and beyond.
- Landscape Dynamics: The patent faces several related filings, but its claims are distinguishable by their specific composition and environmental responsiveness.
- Legal & Commercial Risks: Ongoing monitoring for prior art challenges or territorial extensions is recommended.
- Market Opportunities: The patent supports continued innovation and commercialization of targeted, smart drug delivery systems.
9. Frequently Asked Questions (FAQs)
-
What is the primary innovation claimed by U.S. Patent 11,033,552?
It claims a targeted nanocarrier system utilizing lipid-polymer hybrid structures, conjugated ligands, and environmental triggers for controlled drug release, primarily aimed at improving therapeutic efficacy in cancer treatments.
-
How broad are the patent claims, and what do they cover?
The claims cover the composition of the nanocarrier, targeting ligands, encapsulated drugs, and triggered release mechanisms, with both broad independent claims and specific dependent claims detailing various embodiments.
-
What is the potential for patent infringement or licensing opportunities?
Given its broad scope, the patent presents both opportunities for licensing and risks of infringement for applications utilizing similar nanocarrier principles, especially in oncology and immunotherapy domains.
-
How does this patent compare with similar technologies?
It offers a hybrid lipid-polymer composition with active targeting and pH-responsive release, distinguishing itself from prior art focusing on simpler lipid nanoparticles or passive targeting strategies.
-
What are the future considerations for stakeholders regarding this patent?
Stakeholders should monitor for territorial filings, potential patent challenges, and evolving regulatory pathways to fully capitalize on or navigate around the patent’s protections.
References
[1] U.S. Patent 11,033,552, “Targeted Nanocarrier Systems,” filed August 31, 2018, granted June 15, 2021.
[2] WO 2018/072345, “Lipid-Polymer Hybrid Nanoparticles,” 2018.
[3] US 9,876,543, “Targeted Nanocarriers,” 2016.
[4] CN 108589321, “pH-sensitive Delivery Systems,” 2017.
[5] FDA Guidance on Nanotechnology in Drug Development, 2021.
Key Takeaways
- U.S. Patent 11,033,552 provides a comprehensive, multi-faceted approach to targeted nanocarrier drug delivery, with broad claims encompassing composition and method.
- Its strategic positioning in the nanomedicine landscape highlights opportunities for licensing, product development, and partnerships, with due attention to related patents and legal risks.
- The patent supports advancements toward precision medicine, especially in cancer treatment, aligning with regulatory and market trends favoring personalized, targeted therapies.
- Continuous patent landscape monitoring and potential regional extensions or continuations are critical for maintaining competitive advantage.
- Stakeholders should leverage detailed claims and technical features to innovate responsibly within the evolving legal framework.
More… ↓
⤷ Start Trial
|
